Novartis
East Hanover, New Jersey, 07936, United States
NCT Number: NCT05963282
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blocker (ARB) therapy for HF in the United States (US) using the secondary source of data, Optum Electronic Health Records (EHR).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
East Hanover, New Jersey, 07936, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Sacubitril/valsartan cohort:
ACEi/ARB cohort:
Exclusion criteria
Sacubitril/valsartan cohort:
ACEi/ARB cohort:
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Time frame: Up to approximately 5 years
Novartis Pharmaceuticals
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.